Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: To identify potential molecular prognostic markers in core binding factor (CBF) AML, we analyzed incidences and prognostic impacts of mutations in c-KIT, WT1, CEBPA, CBL, and a number of epigenetic genes in CBF AML. Methods: Seventy one and 21 AML patients with t(8;21) and inv(16) were enrolled in this study, respectively. NPM1, CEBPA, c-KIT, IDH1/2, DNMT3A, EZH2, WT1, and CBL mutations were analyzed by direct sequencing. Patients were categorized with respect to c-KIT and WT1 mutation status, and both clinical features and prognoses were compared. Results: The incidences of FLT3 internal tandem duplication (ITD), NPM1, CEBPA, IDH1/2, DNMT3A, EZH2, and CBL mutations were low (≤5%) in CBF AML patients. However, c-KIT and WT1 mutations occurred frequently (10.9% and 13.8%, respectively). t(8;21) patients with c-KIT mutations showed significantly shorter overall survival (OS) and disease free survival (DFS) periods than those without mutations (P<0.001, for both); however, although the limited number of t(8;21) patients were analyzed, WT1 mutation status did not affect prognosis significantly. Relapse or death during follow-up occurred more frequently in t(8;21) patients carrying c-KIT mutations than in those without the mutation, although the difference was significant only in a specific patient subgroup with no WT1 mutations (P=0.014). Conclusions: The incidences of mutations in epigenetic genes are very low in CBF AML; however, c-KIT and WT1 mutations occur more frequently than others. The poor prognostic impact of c-KIT mutation in t(8;21) AML patients only applies in a specific patient subgroup without WT1 mutations. The prognostic impact of WT1 mutation in CBF AML is not evident and further investigation is required.
Abstract
Background: To identify potential molecular prognostic markers in core binding factor (CBF) AML, we analyzed incidences and prognostic impacts of mutations in c-KIT, WT1, CEBPA, CBL, and a number of epigenetic genes in CBF AML. Methods: Seventy one and 21 AML patients with t(8;21) and inv(16) were enrolled in this study, respectively. NPM1, CEBPA, c-KIT, IDH1/2, DNMT3A, EZH2, WT1, and CBL mutations were analyzed by direct sequencing. Patients were categorized with respect to c-KIT and WT1 mutation status, and both clinical features and prognoses were compared. Results: The incidences of FLT3 internal tandem duplication (ITD), NPM1, CEBPA, IDH1/2, DNMT3A, EZH2, and CBL mutations were low (≤5%) in CBF AML patients. However, c-KIT and WT1 mutations occurred frequently (10.9% and 13.8%, respectively). t(8;21) patients with c-KIT mutations showed significantly shorter overall survival (OS) and disease free survival (DFS) periods than those without mutations (P<0.001, for both); however, although the limited number of t(8;21) patients were analyzed, WT1 mutation status did not affect prognosis significantly. Relapse or death during follow-up occurred more frequently in t(8;21) patients carrying c-KIT mutations than in those without the mutation, although the difference was significant only in a specific patient subgroup with no WT1 mutations (P=0.014). Conclusions: The incidences of mutations in epigenetic genes are very low in CBF AML; however, c-KIT and WT1 mutations occur more frequently than others. The poor prognostic impact of c-KIT mutation in t(8;21) AML patients only applies in a specific patient subgroup without WT1 mutations. The prognostic impact of WT1 mutation in CBF AML is not evident and further investigation is required.
참고문헌 (25)
- Conway O’Brien E, "The epigenetic landscape of acute myeloid leukemia", Adv Hematol, 2014, pp.103175~ (2014)
- Murati A, "Myeloid malignancies: mutations, models and management", BMC Cancer, 12, pp.304~ (2012)
- Kiyoi H, "Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia", Blood, 93, pp.3074~3080 (1999)
- Port M, "Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 yr: a systematic review and meta-analysis", Ann Hematol, 93, pp.1279~1286 (2014)
- Thol F, "Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia", J Clin Oncol, 29, pp.2889~2896 (2011)
- Yan XJ, "Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia", Nat Genet, 43, pp.309~315 (2011)
- Fried I, "Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia", Haematologica, 97, pp.246~250 (2012)
- Marcucci G, "IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study", J Clin Oncol, 28, pp.2348~2355 (2010)
- Wang X, "EZH2 mutations are related to low blast percentage in bone marrow and -7", del(7q) in de novo acute myeloid leukemia, 2013, pp.8, e61341~
- Naoe T, "Gene mutations of acute myeloid leukemia in the genome era", Int J Hematol, 97, pp.165~174 (2013)
- Abdel-Wahab O, "Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms", Leukemia, 25, pp.1200~1202 (2011)
- Rocquain J, "Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias", BMC Cancer, 10, pp.401~ (2010)
- Inoue K, "WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia", Blood, 84, pp.3071~3079 (1994)
- Schmid D, "Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia", Leukemia, 11, pp.639~643 (1997)
- Bergmann L, "Wilms tumor gene expression in acute myeloid leukemias", Leuk Lymphoma, 25, pp.435~443 (1997)
- Miglino M, "WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia", Leuk Lymphoma, 52, pp.1961~1969 (2011)
- Kim HJ, "KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1", RUNX1T1 rearrangement, 2013, pp.92, 163~171
- Park SH, "Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia", Leuk Res, 35, pp.1376~1383 (2011)
- Boissel N, "Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)", Leukemia, 20, pp.965~970 (2006)
- Paschka P, "Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study", J Clin Oncol, 24, pp.3904~3911 (2006)
- Allen C, "The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia", Leukemia, 27, pp.1891~1901 (2013)
- Park SH, "Clinical usefulness of plasma specimens for detection of nucleophosmin 1 gene mutations in patients with normal karyotype acute myeloid leukemia", Leuk Res, 35, pp.e159~160 (2011)
- Park SH, "CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk", Leuk Res, 37, pp.1488~1494 (2013)
- Verhaak RG, "Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance", Blood, 106, pp.3747~3754 (2005)
- Mrózek K, "Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia", Curr Opin Oncol, 20, pp.711~718 (2008)